Limitations of conventional specificity tools have contributed to undetected polyspecificity in antibody drugs. We performed a systematic specificity analysis of preclinical and clinical antibodies and identified a surprisingly high rate of off-target binding throughout the industry, with up to one third of antibody drugs displaying off-target binding. Our findings across different phases of drug development suggest polyspecificity is a major source of drug attrition, and better tools could help to improve drug approvals and patient safety.

In this webinar, we will discuss the emergence of cell-based protein arrays as an alternative and improved technology to evaluate antibody specificity.

Key takeaways:

• Cell-based protein arrays, including Integral Molecular’s Membrane Proteome Array™ (MPA), enable precise assessment of binding interactions
• The MPA identified off-target binding interactions that were missed in tissue cross-reactivity studies
• Early detection of off-target antibody binding can mitigate drug toxicity and attrition